While Johnson & Johnson isn't the first to secure FDA approval for an FcRn-blocking antibody in myasthenia gravis, the New ...

It isn't the first drug in the class to be cleared by the FDA for gMG – Argenx and UCB have FcRn blockers already on the ...

The approval applies to certain patients with myasthenia gravis or chronic inflammatory demyelinating polyneuropathy. An expert said the new option allows patients “to manage their condition ...

Responders to batoclimab in Period 1, defined as ≥2-point improvement in Myasthenia Gravis Activities of ... from Period 1 baseline in adjusted Inflammatory Neuropathy Cause and Treatment ...

Nicholas J. Silvestri, MD, recounts how the 2025 American Academy of Neurology meeting was an exciting and energizing event, particularly in the realm of myasthenia gravis (MG), where numerous new ...

Johnson & Johnson has reported new phase 3 data with its FcRn blocker nipocalimab in generalised myasthenia gravis ... (SLE), idiopathic inflammatory myopathies (IIMs), haemolytic disease of ...

Autoimmune generalized myasthenia gravis is a disease that manifests with fluctuating muscle weakness. Inebilizumab is a monoclonal antibody that depletes CD19+ B cells, which are central to ...

VYVGART is approved for generalized myasthenia gravis (gMG) and immune thrombocytopenia (Japan only). VYVGART Hytrulo is approved for gMG and chronic inflammatory demyelinating polyneuropathy (CIDP).

for the treatment of adult patients with generalized myasthenia gravis (gMG) who are anti-acetylcholine receptor (AChR) antibody positive and adult patients with chronic inflammatory demyelinating ...

Responders to batoclimab in Period 1, defined as ≥2-point improvement in Myasthenia Gravis Activities of ... from Period 1 baseline in adjusted Inflammatory Neuropathy Cause and Treatment ...

Responders to batoclimab in Period 1, defined as ≥2-point improvement in Myasthenia Gravis Activities of Daily Living (MG ... a ≥1 point improvement from Period 1 baseline in adjusted Inflammatory ...